Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. Vazquez-Oliver A, Perez-Garcia S, Romero-Perez R, Pizarro N, et al. Alzheimers Dement 2025;21:e70874.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vazquez-Oliver A, Perez-Garcia S, Romero-Perez R, Pizarro N, et al. Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes. Alzheimers Dement 2025;21:e70874.
PMID: 41257439